Your session is about to expire
← Back to Search
3'-deoxy-3'-[18F]fluorothymidine for Brain Tumor
Study Summary
This trial is looking at using FLT PET imaging to help find, diagnose, and predict treatment response in cancer patients.
- Brain Tumor
- Leukemia
- Lymphoproliferative Disorders
- Multiple Myeloma
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasms
- Solid Tumors
- Myeloproliferative Disorders
- Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the qualifications for participating in this clinical trial?
"In order to qualify for this clinical study, patients must have myelodysplastic syndromes and be within the age range of 18-120. A total of 80 patient are sought after."
How many participants are being enlisted in this clinical investigation?
"Affirmative. According to data accessible on the website of clinicaltrials.gov, this investigation has opened their doors and is seeking participants, with 80 patients needing recruitment from only one site. The trial was initially posted on September 1st 2009 and last updated March 30th 2022."
Are there still slots available for individuals to participate in this clinical research?
"Affirmative. Clinicaltrials.gov displays that this experiment is currently recruiting members, with its first posting on September 1st 2009 and most recent amendment occurring March 30th 2022. A total of 80 patients are needed at one research centre."
Is this investigation enrolling individuals aged over thirty?
"The age range for participation in this research study is 18 to 120 years."
Share this study with friends
Copy Link
Messenger